Novartis: Small Cell Lung Carcinoma trials
The registry lists 14 Small Cell Lung Carcinoma studies with Novartis as lead sponsor. 4 are open to participants now and 2 have results posted.
Phase 1 8Phase 2 7Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of TRB191 in Patients With Extensive-stage Small Cell Lung CancerRecruitingNCT07908667Phase 1
- A Study to Evaluate DJI136, a DLL3-targeted CAR-T TherapyRecruitingNCT07564401Phase 1/2
- Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsRecruitingNCT07006727Phase 1
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsRecruitingNCT06726148Phase 1/2
- [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)TerminatedNCT03724253Phase 2Results posted
- PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic MalignanciesCompletedNCT03365791Phase 2Results posted
- A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.CompletedNCT05329623Phase 1
- A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabActive, not recruitingNCT05142696Phase 1/2
- Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT04507919
- Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer PatientsCompletedNCT00466466Phase 1
- Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
- Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast CancerCompletedNCT00006370Phase 2
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1
- Zoledronate in Treating Patients With Solid Tumors That Have Spread to the BoneCompletedNCT00003884Phase 3